A new immune cell therapy for recurrent glioblastoma
Part of Cancer clinical trials.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of brain cancer called glioblastoma that is recurrent or has not responded to treatment.
- Your tumor cells have high levels of proteins called B7H3 and IL13Ra2 (more than 30% of cells).
- You are able to care for yourself (Karnofsky score of 60% or higher).
- You have not had certain other cancer treatments recently, like chemotherapy or radiation, within the last few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests engineered immune cells (called NK cells) that are designed to fight glioblastoma, a deadly brain cancer. The cells are injected directly into the tumor and may help patients whose cancer has come back after standard treatment.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
This trial tests a new type of CAR T-cell therapy that targets a specific protein (EGFRvIII) found on some glioblastoma cells. The treatment is designed to be more effective and potentially safer for people whose brain tumor has come back after previous treatments.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.